0
0
NEW YORK – April 19, 2025 – A potential breakthrough in maternal mental health is offering new hope, as research advances on a blood test designed to predict postpartum depression (PPD) before symptoms even manifest. This development could pave the way for preventative care, transforming the approach to the most common complication of childbirth.
Postpartum depression affects approximately one in seven women after delivery, characterized by severe depression and anxiety that can hinder bonding with a newborn and, in severe cases, lead to thoughts of self-harm. Suicide remains a leading cause of maternal death in the U.S. Despite its prevalence and severity, factors like stigma, shame, and lack of awareness mean only about 6% of affected women seek medical help, often delaying diagnosis and impacting both mother and child long-term.
However, a decade of research into epigenetic biomarkers – indicators reflecting changes in gene expression – may soon change this landscape. Studies, including one published in Psychiatry Research in 2020, have shown these biomarkers can predict PPD with up to 80% accuracy when tested in the third trimester of pregnancy.
Crucially, these biomarkers have proven effective in predicting PPD in women both with and without a prior history of depression, according to findings from multiple studies. “If these findings can be used to create a standardized blood test, then high-risk patients would be able to seek treatment before symptoms occur,” stated Dr. Lauren Osborne, vice chair of clinical research in Obstetrics and Gynecology at Weill Cornell Medicine and second author of the 2020 study.
Experts believe such a test could revolutionize care. Dr. Jamie Maguire, a neuroscience professor at Tufts University School of Medicine, noted that a predictive test “would alert the clinical care team to the potential risk,” guiding early, targeted interventions and advancing precision medicine in psychiatry.
Furthermore, the test could significantly reduce the stigma surrounding PPD. Dr. Jennifer Payne, a reproductive psychiatry expert at the University of Virginia, highlighted that a blood biomarker provides an objective measure and biological basis, reinforcing PPD as a treatable medical condition. Dr. Payne and Dr. Osborne are leading further research, including a local study already underway and a national study planned for this summer, to explore the test’s potential. Success in these trials could mean the test becomes available within a few years.
Research suggests PPD may present in at least two forms: one linked to a history of depression, and another “hormone-dependent” type affecting women with no prior mental health issues. A predictive test could help tailor treatments accordingly.
Current treatments often combine medication and therapy. Many common antidepressants are considered generally safe during pregnancy. For hormone-dependent PPD, the FDA approved zuranolone (Zurzuvae) in 2023, a neuroactive hormone treatment. Dr. Morgan U. Patterson, Director of the Perinatal Mood and Anxiety Disorders Program at the University of North Carolina School of Medicine, suggested that with a positive biomarker test, patients could potentially start the two-week zuranolone course immediately after birth in the hospital.
Psychotherapy, particularly cognitive behavioral therapy (CBT) and interpersonal therapy, remains vital, helping mothers develop coping skills and process emotions. Group therapy can also combat feelings of isolation. Marilyn Cross Coleman, a perinatal treatment specialist, emphasized that early mental health support is key, as finding care can take time.
While the test is under development, experts stress the importance of existing preventative measures. Research indicates that securing a four- to five-hour block of uninterrupted sleep nightly can help stave off symptoms, though this is challenging with a newborn. Utilizing support networks – family, friends, or even hired help like night nurses – is crucial. Having a proactive plan for mental wellness during the postpartum period is recommended, as “a mother’s environment and support network will play a large part in her recovery,” according to Cross Coleman.
Disclaimer: This article reports on ongoing medical research. The blood test described is currently under investigation in clinical studies and is not yet available for public use. Information regarding treatments and preventative measures should be discussed with qualified healthcare professionals.
